OTC · NAVBQ
Navidea Biopharmaceuticals, Inc.
$0.00$0.00 (0.0%)
Navidea Biopharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.77% below the high.
Loading market information…
OTC · CRXM · USD
Stock price, earnings
Quote as of Oct 14, 2024, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Gene Biotherapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Gene Biotherapeutics, Inc. is a biotechnology company in the clinical development stage, dedicated to researching and bringing to market angiogenic gene therapy treatments for cardiovascular conditions across the United States. Its primary investigational compound, Generx, an angiogenic gene therapy candidate, is currently undergoing Phase 3 clinical trials. Generx aims to offer a potential treatment for individuals suffering from myocardial ischemia and severe, intractable angina, typically caused by advanced coronary artery disease. Furthermore, the company is exploring Generx's potential for other therapeutic applications related to ischemia affecting both the cardiovascular and cerebral systems. For the production of its Generx angiogenic gene therapy during these pivotal Phase 3 evaluations, Gene Biotherapeutics has established a manufacturing partnership with Fujifilm Diosynth Biotechnologies. Founded in 2003, the company is headquartered in San Diego, California. It officially rebranded as Gene Biotherapeutics, Inc. in January 2018, having previously operated under the name Taxus Cardium Pharmaceuticals Group, Inc.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:20 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.00$0.00 (0.0%)
Navidea Biopharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.77% below the high.
$0.01$0.00 (0.0%)
NeonMind Biosciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.67% below the high.
$0.00$0.00 (0.0%)
Gelesis Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.0% below the high.
$0.00-$0.04 (-99.5%)
E-Qure Corp.: Healthcare · Medical - Devices.
$0.00$0.00 (0.0%)
Capha Pharmaceuticals Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
Acacia Diversified Holdings, Inc.: Healthcare · Drug Manufacturers - Specialty & Generic.
$0.00-$0.04 (-99.75%)
American CryoStem Corporation: Healthcare · Biotechnology.
$0.00+$0.00 (0.0%)
GeneThera, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.33% below the high.
